Skovdahl Helene Kolstad, Gopalakrishnan Shreya, Svendsen Tarjei Dahl, Granlund Atle van Beelen, Bakke Ingunn, Ginbot Zekarias G, Thorsvik Silje, Flatberg Arnar, Sporsheim Bjørnar, Ostrop Jenny, Mollnes Tom Eirik, Sandvik Arne Kristian, Bruland Torunn
Department of Clinical and Molecular Medicine (IKOM), Faculty of Medicine and Health Sciences, NTNU- Norwegian University of Science and Technology, Trondheim, Norway.
Centre of Molecular Inflammation Research (CEMIR), Faculty of Medicine and Health Sciences, NTNU- Norwegian University of Science and Technology, Trondheim, Norway.
Front Pharmacol. 2021 May 13;12:679741. doi: 10.3389/fphar.2021.679741. eCollection 2021.
Treatment of inflammatory bowel disease (IBD) is challenging, with a series of available drugs each helping only a fraction of patients. Patients may face time-consuming drug trials while the disease is active, thus there is an unmet need for biomarkers and assays to predict drug effect. It is well known that the intestinal epithelium is an important factor in disease pathogenesis, exhibiting physical, biochemical and immunologic driven barrier dysfunctions. One promising test system to study effects of existing or emerging IBD treatments targeting intestinal epithelial cells (IECs) is intestinal organoids ("mini-guts"). However, the fact that healthy intestinal epithelium is in a physiologically hypoxic state has largely been neglected, and studies with intestinal organoids are mainly performed at oxygen concentration of 20%. We hypothesized that lowering the incubator oxygen level from 20% to 2% would recapitulate better the physiological environment of colonic epithelial cells and enhance the translational value of intestinal organoids as a drug testing platform. In the present study we examine the effects of the key IBD cytokines and drug targets TNF/IL17 on human colonic organoids (colonoids) under atmospheric (20%) or reduced (2%) O. We show that colonoids derived from both healthy controls and IBD-patients are viable and responsive to IBD-relevant cytokines at 2% oxygen. Because chemokine release is one of the important immunoregulatory traits of the epithelium that may be fine-tuned by IBD-drugs, we also examined chemokine expression and release at different oxygen concentrations. We show that chemokine responses to TNF/IL17 in organoids display similarities to inflamed epithelium in IBD-patients. However, inflammation-associated genes induced by TNF/IL17 were attenuated at low oxygen concentration. We detected substantial oxygen-dependent differences in gene expression in untreated as well as TNF/IL17 treated colonoids in all donors. Further, for some of the IBD-relevant cytokines differences between colonoids from healthy controls and IBD patients were more pronounced in 2% O than 20% O. Our results strongly indicate that an oxygen concentration similar to the epithelial cell environment is of essence in experimental pharmacology.
炎症性肠病(IBD)的治疗具有挑战性,一系列可用药物仅对一小部分患者有效。在疾病活动期间,患者可能要面临耗时的药物试验,因此对预测药物疗效的生物标志物和检测方法存在未满足的需求。众所周知,肠道上皮是疾病发病机制中的一个重要因素,表现出物理、生化和免疫驱动的屏障功能障碍。一种有前景的用于研究现有或新出现的针对肠道上皮细胞(IECs)的IBD治疗效果的测试系统是肠道类器官(“迷你肠道”)。然而,健康肠道上皮处于生理低氧状态这一事实在很大程度上被忽视了,并且肠道类器官的研究主要在20%的氧气浓度下进行。我们假设将培养箱中的氧气水平从20%降至2%能更好地模拟结肠上皮细胞的生理环境,并提高肠道类器官作为药物测试平台的转化价值。在本研究中,我们研究了关键的IBD细胞因子和药物靶点TNF/IL17在大气(20%)或低氧(2%)条件下对人结肠类器官(结肠小体)的影响。我们发现,来自健康对照和IBD患者的结肠小体在2%氧气浓度下是有活力的,并且对与IBD相关的细胞因子有反应。由于趋化因子释放是上皮细胞重要的免疫调节特性之一,可能会被IBD药物微调,我们还研究了不同氧气浓度下趋化因子的表达和释放。我们发现类器官中趋化因子对TNF/IL17的反应与IBD患者炎症上皮的反应相似。然而,TNF/IL17诱导的炎症相关基因在低氧浓度下会减弱。我们在所有供体未经处理以及经TNF/IL17处理的结肠小体中检测到了基因表达上显著的氧依赖性差异。此外,对于一些与IBD相关的细胞因子,健康对照和IBD患者的结肠小体之间的差异在2%氧气浓度下比在20%氧气浓度下更明显。我们的结果强烈表明,与上皮细胞环境相似的氧气浓度在实验药理学中至关重要。